What is B. Riley’s Estimate for RIGL FY2026 Earnings?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Investment analysts at B. Riley upped their FY2026 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a research note issued to investors on Tuesday, March 4th. B. Riley analyst K. Patel now forecasts that the biotechnology company will post earnings per share of $1.08 for the year, up from their prior estimate of $0.97. B. Riley currently has a “Neutral” rating and a $24.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released its quarterly earnings results on Tuesday, March 4th. The biotechnology company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.50. The firm had revenue of $57.60 million for the quarter, compared to analyst estimates of $57.59 million. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%.

Several other equities analysts also recently issued reports on RIGL. StockNews.com downgraded Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Citigroup lifted their price target on Rigel Pharmaceuticals from $49.00 to $55.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $57.00 price objective on shares of Rigel Pharmaceuticals in a report on Wednesday. Piper Sandler boosted their target price on shares of Rigel Pharmaceuticals from $15.00 to $23.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald increased their price target on shares of Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Rigel Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $36.80.

Rigel Pharmaceuticals Price Performance

Shares of RIGL opened at $19.70 on Thursday. The company has a market capitalization of $347.02 million, a P/E ratio of 140.72 and a beta of 1.35. Rigel Pharmaceuticals has a one year low of $7.48 and a one year high of $29.82. The business’s 50 day simple moving average is $20.09 and its 200-day simple moving average is $18.42.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new position in Rigel Pharmaceuticals during the fourth quarter worth about $63,000. Wells Fargo & Company MN boosted its stake in Rigel Pharmaceuticals by 44.5% during the 4th quarter. Wells Fargo & Company MN now owns 8,603 shares of the biotechnology company’s stock worth $145,000 after acquiring an additional 2,648 shares during the last quarter. SG Americas Securities LLC grew its holdings in Rigel Pharmaceuticals by 42.8% during the fourth quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 2,827 shares during the period. Graham Capital Management L.P. acquired a new position in Rigel Pharmaceuticals during the fourth quarter valued at approximately $170,000. Finally, Integrated Quantitative Investments LLC bought a new stake in Rigel Pharmaceuticals in the fourth quarter valued at approximately $181,000. Institutional investors own 66.23% of the company’s stock.

Insider Buying and Selling at Rigel Pharmaceuticals

In other Rigel Pharmaceuticals news, CEO Raul R. Rodriguez sold 4,952 shares of Rigel Pharmaceuticals stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total transaction of $103,595.84. Following the completion of the sale, the chief executive officer now owns 243,854 shares of the company’s stock, valued at approximately $5,101,425.68. The trade was a 1.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David A. Santos sold 2,125 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total value of $44,455.00. Following the completion of the transaction, the executive vice president now directly owns 53,500 shares in the company, valued at approximately $1,119,220. This trade represents a 3.82 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,113 shares of company stock worth $190,644. Company insiders own 9.04% of the company’s stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.